


# CAPILLARY ELECTROPHORESIS METHODS FOR PHARMACEUTICAL ANALYSIS

Edited by  
Satinder Ahuja  
M. Ilias Jimidar



VOLUME 9

Series Editor **Satinder Ahuja**



## SEPARATION SCIENCE AND TECHNOLOGY



# CAPILLARY ELECTROPHORESIS METHODS FOR PHARMACEUTICAL ANALYSIS

*Edited by*

**Satinder Ahuja**

*Ahuja Consulting, Inc., Calabash, North Carolina*

**M. Ilias Jimidar**

*Johnson and Johnson Pharmaceutical Research and Development, Belgium*



*Amsterdam — Boston — Heidelberg — London  
New York — Oxford — Paris — San Diego  
San Francisco — Singapore — Sydney — Tokyo*



Academic Press is an imprint of Elsevier  
84 Theobald's Road, London WC1X 8RR, UK  
Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands  
Linacre House, Jordan Hill, Oxford OX2 8DP, UK  
30 Corporate Drive, Suite 400, Burlington, MA 01803, USA  
525 B Street, Suite 1900, San Diego, CA 92101-4495, USA

First edition 2008

Copyright © 2008 Elsevier Inc. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: [permissions@elsevier.com](mailto:permissions@elsevier.com). Alternatively you can submit your request online by visiting the Elsevier web site at <http://www.elsevier.com/locate/permissions>, and selecting *Obtaining permission to use Elsevier material*

#### Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made

ISBN: 978-0-12-372573-8

ISSN: 0149-6395

For information on all Academic Press publications  
visit our website at [books.elsevier.com](http://books.elsevier.com)

Printed and bound in USA

08 09 10 11 12 10 9 8 7 6 5 4 3 2 1

Working together to grow  
libraries in developing countries

[www.elsevier.com](http://www.elsevier.com) | [www.bookaid.org](http://www.bookaid.org) | [www.sabre.org](http://www.sabre.org)

ELSEVIER

BOOK AID  
International

Sabre Foundation

**CAPILLARY ELECTROPHORESIS  
METHODS FOR  
PHARMACEUTICAL ANALYSIS**

This is Volume 9 of  
**SEPARATION SCIENCE AND TECHNOLOGY**  
*A reference series edited by Satinder Ahuja*

# PREFACE

Capillary electrophoresis (CE) using fused-silica capillaries with internal diameter in the micrometer range was introduced in 1981 and was received with great enthusiasm in the separations world because it promised high separation efficiency, a large degree of flexibility during method development, and a low cost of operation. After a better understanding of the fundamentals was developed, the focus shifted to some real applications. Many papers describing highly efficient separation methods have been published in the last two decades. CE offers several advantages over high-performance liquid chromatography (HPLC), a technique commonly used in the pharmaceutical industry. These include simplicity, smaller sample size, rapid analysis, automation, ruggedness, different mechanisms for selectivity, and low cost. Furthermore, CE offers higher efficiency than HPLC and thus greater resolution power for separating various components. These advantages make CE a very attractive tool in the research and development of pharmaceuticals, quality control, and stability studies.

This book has been planned to provide busy pharmaceutical scientists a complete yet concise reference guide for utilizing the versatility of CE in new drug development and quality control. The text can be broadly classified in five major sections:

- Overview, theory, and instrumentation (Chapters 1–3)
- CE methods and practices (Chapters 4–6)
- Regulatory aspects (Chapters 7–11)
- Applications (Chapters 12–16)
- New developments (Chapters 17 and 18)

Each of the chapters, written by selected experts in their respective fields, is designed to provide the reader with an in-depth understanding of CE theory, hardware, methodologies, regulations, and applications. The text includes state-of-the-art information on CE analysis of

pharmaceuticals and provides the reader a clear and concise understanding of the following important topics:

- How to improve performance of CE methods
- How to develop and validate robust methods in CE
- How to increase precision in CE
- How to make CE method transfers more successful
- How to interpret ICH guidelines relating to CE
- How to perform IQ, OQ, PQ, and CE calibrations

Major applications covered include assays, impurity testing, high-throughput screening, chiral separation,  $pK_a$  determination, ion analysis, impurity profiling, orthogonal method, and characterization of proteins, peptides, and nucleotides. Furthermore, the latest developments in capillary electrochromatography (CEC), CE–MS, and coupling chip-based devices to MS are discussed at length.

We would like to thank all of the authors for their valuable efforts in making this book serve as a definitive reference source on CE for laboratory analysts, researchers, managers/executives in industry, academia, and government who are engaged in various phases of analytical research and development or in quality control.

Satinder Ahuja  
M. Ilias Jimidar

# CONTRIBUTORS

- J.K. Adu** Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland
- Satinder Ahuja** Ahuja Consulting, 1061 Rutledge Court, NW, Calabash, NC 28467, USA
- Gary Camblin** Analytical Sciences, Amgen Inc., 4000 Nelson Road, Longmont, CO 80530, USA
- François de l'Escaille** Analis s.a./n.v., R&D Diag., Zoning Industriel de Rhisnes, Rue de Néverlée 11, B-5020 Suarlée (Namur), Belgium
- Bieke Dejaegher** Department of Analytical Chemistry and Pharmaceutical Technology, Pharmaceutical Institute, Vrije Universiteit Brussel – VUB, Laarbeeklaan 103, B-1090 Brussels, Belgium
- Maurits De Smet** Analytical Development R&D, Johnson & Johnson Pharmaceutical Research & Development, A division of Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse, Belgium
- Melanie Dumarey** Department of Analytical Chemistry and Pharmaceutical Technology, Pharmaceutical Institute, Vrije Universiteit Brussel – VUB, Laarbeeklaan 103, B-1090 Brussels, Belgium
- M.R. Euerby** AstraZeneca R&D Charnwood/Lund, Pharmaceutical and Analytical R&D, Loughborough, England
- Jean-Bernard Falmagne** Analis s.a./n.v., R&D Diag., Zoning Industriel de Rhisnes, Rue de Néverlée 11, 5020 Suarlée (Namur), Belgium
- Chantal Felten** Quality Control Analytical Technologies, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
- Oliver Grosche** Novartis Pharma K.K., Technical R&D Japan, Tsukuba Research Institute, Okubo 8, Tsukuba City, Ibaraki 300-2611, Japan
- Amy Guo** Analytical Sciences, Amgen Inc., 1201 Amgen Court West, Seattle, WA 98119, USA
- Mei Han** Analytical Sciences, Amgen Inc., 1201 Amgen Court West, Seattle, WA 98119, USA
- Ulrike Holzgrabe** Department of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, D-97074 Würzburg, Germany



- Jos Hoogmartens** Laboratory of Pharmaceutical Analysis, K.U. Leuven, O&N2, PB 923, Herestraat 49, B-3000 Leuven, Belgium
- M. Ilias Jimidar** Analytical Development R&D, Johnson & Johnson Pharmaceutical Research & Development, A division of Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse, Belgium
- Swapna Mallampati** Laboratory of Pharmaceutical Analysis, K.U. Leuven, O&N2, PB 923, Herestraat 49, B-3000 Leuven, Belgium
- Charlie Meert** Analytical Sciences, Amgen Inc., 1201 Amgen Court West, Seattle, WA 98119, USA
- Pim G. Muijselaar** Solvay Pharmaceuticals, C.J. van Houtenlaan 36, 1381 CP Weesp, The Netherlands
- Brian K. Nunnally** Wyeth, 4300 Oak Park, Sanford, NC 27330, USA
- Brian O'Flaherty** Groton Biosystems, 85 Swanson Road, Boxborough, MA 01719, USA
- Sungae Park** Formulation and Analytical Resource Group, Amgen Inc., Thousand Oaks, CA, USA
- Jochen Pauwels** Laboratory of Pharmaceutical Analysis, K.U. Leuven, O&N2, PB 923, Herestraat 49, B-3000 Leuven, Belgium
- Barrie Puttock** Renwood Validation Services Ltd., 135 Rother Crescent, Gossops Green, Crawley, RH11 8LR, West Sussex, UK
- Serge Rudaz** Laboratory of Pharmaceutical Analytical Chemistry, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Bd d'Yvoy 20, CH-1211 Geneva 4, Switzerland
- Oscar Salas-Solano** Late Stage Analytical Development, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
- Cari E. Sanger-van de Griend** Solvay Pharmaceuticals, Chemical and Pharmaceutical Development, C.J. van Houtenlaan 36, 1381 CP Weesp, The Netherlands
- Julie Schappler** Laboratory of Pharmaceutical Analytical Chemistry, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Bd d'Yvoy 20, CH-1211 Geneva 4, Switzerland
- G.G. Skellern** Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland
- J.N.A. Tettey** Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland
- Yvan Vander Heyden** Department of Analytical Chemistry and Pharmaceutical Technology, Pharmaceutical Institute, Vrije Universiteit Brussel – VUB, Laarbeeklaan 103, B-1090 Brussels, Belgium
- Willy Van Ael** Analytical Development R&D, Johnson & Johnson Pharmaceutical Research & Development, A division of Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse, Belgium
- Patrick Van Nyen** Analytical Development R&D, Johnson & Johnson Pharmaceutical Research & Development, A division of Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse, Belgium
- Ann Van Schepdael** Laboratory of Pharmaceutical Analysis, K.U. Leuven, O&N2, PB 923, Herestraat 49, B-3000 Leuven, Belgium
- Jean-Luc Veuthey** Laboratory of Pharmaceutical Analytical Chemistry, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Bd d'Yvoy 20, CH-1211 Geneva 4, Switzerland
- Hermann Watzig** Institute of Pharmaceutical Chemistry, Technical University, Braunschweig, 38106 Braunschweig, Germany
- Markus Zeitz** Novartis Pharma, Basel, Switzerland

# CONTENTS

**PREFACE** xiii

**CONTRIBUTORS** xv

## **I. Overview of Capillary Electrophoresis in Pharmaceutical Analysis**

SATINDER AHUJA

- I. Introduction 1
- II. Various Modes of CE 2
- III. Instrumentation 3
- IV. Method Development for Pharmaceutical Analysis 3
- V. Analysis of Active Pharmaceutical Ingredients and Drug Products 3
- VI. General Considerations for Improving Performance of CE Methods 4
- VII. Current Regulatory Guidance 4
- VIII. Qualification of Capillary Electrophoresis Instrumentation 4
- IX. Robustness Tests of CE Methods 5
- X. Validation of Analytical Methods 5
- XI. The Need for CE Methods in Pharmacopoeias 5
- XII. CE in Impurity Profiling of Drugs 6
- XIII. Ion Analysis Using Capillary Electrophoresis 6
- XIV. Role of CE in Biopharmaceutical Development and QC 6
- XV. Capillary Electrophoresis and Bioanalysis 7
- XVI. CE as an Orthogonal Technique to Chromatography 7
- XVII. Capillary Electrochromatography of Pharmaceuticals 7
- XVIII. Coupling CE and Microchip-Based Devices with Mass Spectrometry 7
- References 8

## **2. Theoretical Considerations in Performance of Various Modes of CE**

M. ILIAS JIMIDAR

- Abstract 9
- I. Introduction 10
- II. Basic CE Configuration 11
- III. CE Characteristics 12
- IV. Principles of CE 17
- V. Methods and Modes in CE 31
- VI. Summary and Conclusions 39
- References 40

## **3. Equipment Considerations for Capillary Electrophoresis**

BRIAN O'FLAHERTY AND BRIAN K. NUNNALLY

- Abstract 43
- I. Capillary Electrophoresis Instrumentation 44
- II. Equipment-Related Issues 56
- III. Validation and Compliance Requirements 57
- IV. Future Developments 59
- V. Summary 61
- References 61

## **4. Method Development for Pharmaceutical Analysis**

M. ILIAS JIMIDAR, PATRICK VAN NYEN, WILLY VAN AEL, AND MAURITS DE SMET

- Abstract 64
- I. Introduction 64
- II. CE Method Types Used in QC Testing 66
- III. Method Development Process 69
- IV. Planning Phase 70
- V. Method Development and Optimization 74
- VI. System Suitability Tests and Limits 80
- VII. Draft Method Description and Method Evaluation Phase 90
- VIII. Method Validation Phase 90
- IX. Method Transfer Phase 90
- X. Method Performance Monitoring and Feedback 93
- XI. Summary and Conclusions 93
- References 94

## **5. Role of CE in Drug Substance and Drug Product Development**

OLIVER GROSCHKE AND MARKUS ZEITZ

Abstract 95

- I. Introduction 96
- II. When Should CE Be Applied in Drug Development? 98
- III. Capillary Electrophoresis in the Drug Development Process, from Candidate Selection to the Market 102
- IV. Pharmaceutical Substances in Literature 119
- V. Summary and Conclusions 119
- References 119

## **6. General Considerations to Improve Performance of CE Methods**

CARIE SÄNGER-VAN DE GRIEND

Abstract 124

- I. Introduction 124
- II. Capillary 125
- III. Electrodes 127
- IV. Temperature 127
- V. Preconditioning 128
- VI. Injection 129
- VII. Applied Voltage 132
- VIII. Background Electrolyte 132
- IX. Detection and Signal Integration 138
- X. Summary and Conclusions 140
- Acknowledgments 140
- References 140

## **7. Overview of Current Regulatory Guidance**

PIM G. MUIJSELAAR

Abstract 145

- I. Introduction 145
- II. Regulatory Guidance Documents 146
- III. Capillary Electrophoresis in Pharmacopoeias 151
- IV. Conclusions 163
- References 164

## **8. Qualification of CE Instrumentation**

BARRIE PUTTOCK

Abstract 171

- I. Introduction 171
- II. Parameters for Qualification 174
- III. Computer System 175
- IV. Keeping the Instrument Qualified 183
- References 183

## **9. Robustness Testing of CE Methods**

BIEKE DEJAEGER AND YVAN VANDER HEYDEN

Abstract 186

- I. Introduction 186
- II. Aims/Objectives and Steps in a Robustness Test 187
- III. Selection of Factors and Levels 189
- IV. Selection of Experimental Designs 194
- V. Selection of Responses 198
- VI. Planning and Execution of Experimental Work 199
- VII. Analysis of Results 201
- VIII. Determination of SST Limits 208
- IX. Review of Case Studies 210
- X. Summary and Conclusions 219
- References 220

## **10. Validation of Analytical Methods Using Capillary Electrophoresis**

HERMANN WÄTZIG

Abstract 225

- I. Method Validation 226
- II. Instrument Qualification 240
- III. Method Transfer 242
- IV. Summary 243
- Abbreviations 243
- References 243

## **11. The Need for CE Methods in Pharmacopoeial Monographs**

ULRIKE HOLZGRABE

Abstract 245

- I. Introduction 245
- II. Key Factor for the Development of a Robust CE Method and Validation 247

- III. Overcoming the Problem of Low Sensitivity 248
- IV. Methods in the European Pharmacopoeia 249
- V. Chiral Analysis 253
- VI. Conclusions 255
- Acknowledgments 256
- References 256

## **12. CE in Impurity Profiling of Drugs**

SWAPNA MALLAMPATI, JOCHEN PAUWELS,  
JOS HOOGMARTENS, AND ANN VAN SCHEPDAEL

- Abstract 259
- I. Introduction 259
- II. Overview of CE Applications in Impurity Profiling 261
- III. Concluding Remarks 299
- References 299

## **13. Ion Analysis Using Capillary Electrophoresis**

FRANÇOIS DE L'ESCAILLE AND JEAN-BERNARD FALMAGNE

- Abstract 317
- I. Introduction 318
- II. General Principle 319
- III. Method Development and Optimization 333
- IV. Applications 338
  - Case Study 1: Example of Counterion Determination 339
  - Case Study 2: Example of a Feasibility Study for Impurity Profiling 348
- V. Conclusions 351
- References 351

## **14. Role of CE in Biopharmaceutical Development and Quality Control**

AMY GUO, GARY CAMBLIN, MEI HAN, CHARLIE MEERT, AND  
SUNGAE PARK

- Abstract 358
- I. Introduction 358
- II. Method Development and Qualification 358
- III. Method Transfer 389
- IV. Method Performance in QC Environment 391
- V. Lessons Learned 392

- VI. Conclusions 392
- Acknowledgments 392
- Appendix: Troubleshooting Examples 393
- References 398

## **15. Capillary Electrophoresis and Bioanalysis**

OSCAR SALAS-SOLANO AND CHANTAL FELTEN

- Abstract 401
- I. Introduction 402
- II. Capillary Electrophoresis Sodium Dodecyl Sulfate (CE-SDS) 402
- III. Effect of Sample Preparation on CE-SDS and SDS-PAGE Analysis of rMAbs 406
- IV. Capillary Zone Electrophoresis 412
- V. Capillary Isoelectric Focusing 413
- VI. Carbohydrate Analysis by CE-LIF 417
- VII. CE and Quality Control Testing of Therapeutic Proteins 418
- VIII. Conclusions 422
- Acknowledgments 423
- References 423

## **16. CE as an Orthogonal Technique to Chromatography**

MELANINE DUMAREY AND YVAN VANDER HEYDEN

- Abstract 425
- I. Introduction 426
- II. Orthogonal Chromatographic Systems 427
- III. CE as an Orthogonal Technique 433
- IV. Conclusions 435
- References 435

## **17. Capillary Electrochromatography of Pharmaceuticals**

J.K. ADU, M.R. EUERBY, J.N.A. TETTEY, AND G.G. SKELLERN

- Abstract 440
- I. Introduction 440
- II. Factors Affecting the Electrophoretic and Chromatographic Parameters in CEC 442
- III. Column Technology in CEC 450
- IV. Types of Columns Used in CEC 451
- V. Analyte Detection in CEC 458

- VI. Applications of Capillary Electrochromatography 461
- VII. Two-Dimensional Separations 467
- VIII. Validating CEC Methods for Pharmaceutical Analysis 469
- IX. CEC—Prospects and Potentials 470
- References 470

## **18. Coupling CE and Microchip-Based Devices with Mass Spectrometry**

JULIE SCHAPPLER, JEAN-LUC VEUTHEY, AND SERGE RUDAZ

- Abstract 477
- I. Introduction 478
- II. CE—MS Coupling and Instrumentation 478
- III. Applications 484
- IV. Quantitative Aspects 493
- V. New Devices 494
- VI. Summary and Conclusions 499
- Abbreviations 500
- References 501

## **SUBJECT INDEX 523**



# OVERVIEW OF CAPILLARY ELECTROPHORESIS IN PHARMACEUTICAL ANALYSIS

**SATINDER AHUJA**

*Ahuja Consulting, 1061 Rutledge Court, NW, Calabash, NC 28467, USA*

- I. INTRODUCTION
- II. VARIOUS MODES OF CE
- III. INSTRUMENTATION
- IV. METHOD DEVELOPMENT FOR PHARMACEUTICAL ANALYSIS
- V. ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS AND DRUG PRODUCTS
- VI. GENERAL CONSIDERATIONS FOR IMPROVING PERFORMANCE OF CE METHODS
- VII. CURRENT REGULATORY GUIDANCE
- VIII. QUALIFICATION OF CAPILLARY ELECTROPHORESIS INSTRUMENTATION
- IX. ROBUSTNESS TESTS OF CE METHODS
- X. VALIDATION OF ANALYTICAL METHODS
- XI. THE NEED FOR CE METHODS IN PHARMACOPOEIAS
- XII. CE IN IMPURITY PROFILING OF DRUGS
- XIII. ION ANALYSIS USING CAPILLARY ELECTROPHORESIS
- XIV. ROLE OF CE IN BIOPHARMACEUTICAL DEVELOPMENT AND QC
- XV. CAPILLARY ELECTROPHORESIS AND BIOANALYSIS
- XVI. CE AS AN ORTHOGONAL TECHNIQUE TO CHROMATOGRAPHY
- XVII. CAPILLARY ELECTROCHROMATOGRAPHY OF PHARMACEUTICALS
- XVIII. COUPLING CE AND MICROCHIP-BASED DEVICES WITH MASS SPECTROMETRY
- REFERENCES

## I. INTRODUCTION

Electrophoresis is a separation technique that is based on the differential migration of charged compounds in a semi-conductive medium under the influence of an electric field. Its origin can be traced back to the 1880s; however, it got major recognition in 1937, when Arne